0001640334-22-000716.txt : 20220510 0001640334-22-000716.hdr.sgml : 20220510 20220406164818 ACCESSION NUMBER: 0001640334-22-000716 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220406 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NYMOX PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0001018735 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 BUSINESS PHONE: 1-800-936-9669 MAIL ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 CORRESP 1 filename1.htm nymox_corresp.htm

 

NYMOX PHARMACEUTICAL CORPORATION

Bay & Deveaux Streets, Nassau, The Bahamas

 

April 6, 2022

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street N.E.

Washington, D.C. 20549

 

Re:

Nymox Pharmaceutical Corporation

Registration Statement on Form F-3

File No. 333-263932

Acceleration Request

Requested Date: April 12, 2022, 11:00 am Eastern Standard Time

 

Gentlemen and Ladies:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nymox Pharmaceutical Corporation, a Bahamian corporation (the “Company”) hereby requests that the above-referenced Registration Statement on Form F-3 (File No. 333-263932) be declared effective at the “Requested Date” set forth above or as soon thereafter as practicable.

 

In connection with the acceleration request, the Company hereby acknowledges that:

 

 

·

 should the Securities and Exchange Commission (the “Commission”) or the staff of the Division of Corporation Finance of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement on Form F-3(the “Filing”) effective, it does not foreclose the Commission from taking any action with respect to the Filing;

 

·

 the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Filing; and

 

·

 the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

   

Thank you for your courtesies and please contact us at your convenience if you require any additional information.

 

Very truly yours,

 

 

 

 

/s/ Paul Averback

 

Paul Averback

 

Chief Executive Officer and President